Researchers at Genentech have demonstrated that direct injection of human alpha-synuclein pre-formed fibrils into the substantia nigra of transgenic mice induces rapid, bilateral neurodegeneration and blood-brain barrier compromise within 60 days. Published in Discover Neuroscience, the study presents a novel animal model that recapitulates multiple pathological hallmarks of Parkinson’s disease with greater speed and severity than previous intrastriatal injection models. The findings suggest that targeting the deep midbrain structures may accelerate the spread of synuclein pathology, offering a valuable platform for testing therapeutic strategies aimed at human alpha-synuclein aggregation.
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the accumulation of alpha-synuclein proteins and the subsequent loss of dopaminergic neurons in the substantia nigra. While existing transgenic mouse models, such as the M83 line overexpressing the A53T mutation, develop synuclein inclusions and gliosis, they typically require extensive aging to exhibit significant dopaminergic degeneration.
To address this gap, the study team unilaterally injected 10 micrograms of human alpha-synuclein pre-formed fibrils directly into the substantia nigra pars compacta of A53T alpha-synuclein transgenic mice. The animals were monitored for 60 days post-injection, a timeframe significantly shorter than the 80 to 90 days typically required for similar phenotypes to emerge in intrastriatal models.
Examination of brain sections revealed a robust bilateral spreading of phosphorylated alpha-synuclein, specifically the pS129 isoform, throughout the midbrain, striatum, and cerebral cortex. Quantitative analysis showed significant elevations in pS129 intensity in both the ipsilateral and contralateral hemispheres compared to saline-injected controls, with the pathology being more pronounced on the injected side. The spread of this pathology to distal brain regions, including the olfactory bulb and hippocampus, aligns with the prion-like propagation hypothesis of Parkinson’s disease, where misfolded proteins travel along synaptically connected pathways.
Concomitant with the spread of synuclein pathology, the mice exhibited significant neuroinflammation. Staining for CD68, a marker for activated microglia, revealed a substantial increase in microglial activation in the substantia nigra, cortex, and striatum of the injected animals. The study found a strong positive correlation between CD68-positive neuroinflammation and alpha-synuclein-associated pathology in the midbrain, suggesting that microglial activation is closely linked to the burden of synuclein aggregates. Additionally, immunofluorescence staining for Iba1 confirmed increased microglial intensity and clustering in the cerebral cortex and midbrain.
A critical finding of the study was the significant loss of tyrosine hydroxylase (TH) intensity, a key indicator of dopaminergic neurodegeneration. Using an automated artificial intelligence-based workflow to segment and analyze the substantia nigra pars compacta and reticulata, the researchers observed a 50% reduction in TH intensity in the injected mice compared to controls. A similar 40% reduction was noted in the striatum, representing the loss of TH-positive axonal projections from the substantia nigra. This bilateral degeneration, despite the unilateral nature of the injection, highlights the interhemispheric spread of pathological seeds through neuronal connectivity.
The study also uncovered a compromised blood-brain barrier (BBB) in the PFF-injected animals. Immunostaining for Collagen IV, a structural protein of the BBB basal membrane, showed a two-fold decrease in expression in the injected mice, indicating impaired structural integrity. This compromise was further evidenced by the extravasation of murine IgG into the brain parenchyma, particularly in the substantia nigra, striatum, and cortex. The presence of IgG in these regions suggests that the BBB leakage allows peripheral immune components to enter the central nervous system, a phenomenon previously observed in post-mortem human Parkinson’s disease brains.
Associated with the BBB compromise was a significant infiltration of T cells into the brain. Immunostaining for the T-cell marker CD3 revealed increased counts of T cells in the midbrain, hippocampus, and cortex of the PFF-injected mice. The study noted a positive correlation between T-cell infiltration, pS129 pathology, and CD68-positive neuroinflammation, suggesting a complex crosstalk between peripheral immune cells and resident microglia. The absence of T-cell infiltration in saline-injected controls indicates that this phenotype is driven by the interaction between the injected fibrils and the transgenic background, rather than the surgical procedure alone.
Behavioral assessments further supported the severity of the induced pathology. PFF-injected mice experienced body weight loss, reduced rearing behavior, and increased hind-limb paralysis by the 60-day timepoint. These motor deficits were more rapid and severe than those observed in previous intrastriatal models, where similar symptoms typically emerged later in the disease course. The accelerated timeline of this model allows for faster evaluation of potential therapeutics, as significant phenotypic changes are detectable within two months of injection.
The authors acknowledge several limitations of the model, including the artificial nature of direct intranigral injection and the use of a transgenic background with an overexpressed rare mutation not present in the majority of Parkinson’s patients. However, they argue that the model’s ability to recapitulate multiple PD-associated phenotypes, including synuclein spread, neuroinflammation, BBB compromise, and dopaminergic loss, makes it a powerful tool for preclinical research. The study provides a detailed framework for understanding the temporal and spatial dynamics of synuclein pathology when seeded in the midbrain.
By demonstrating that direct seeding in this region accelerates disease progression, the study offers new insights into the mechanisms of neurodegeneration and immune response. The development of this rapid-acting model may facilitate the screening of drugs that target human alpha-synuclein, potentially accelerating the translation of therapeutic candidates to clinical trials.
The integration of AI-based analysis for tyrosine hydroxylase quantification represents a methodological advancement in the field, providing a rapid and unbiased assessment of neuronal health. The study’s comprehensive characterization of the model, from molecular pathology to behavioral outcomes, establishes a robust standard for future investigations into the pathophysiology of synucleinopathies.
As researchers continue to explore the complex interactions between protein aggregation, neuroinflammation, and immune infiltration, this model serves as a vital resource for dissecting the multifaceted nature of Parkinson’s disease. The findings underscore the importance of considering the location of pathology seeding when designing animal models, as the site of injection can significantly influence the rate and extent of disease progression. This work paves the way for more targeted and efficient preclinical studies aimed at developing effective treatments for Parkinson’s disease.
Subject of Research: Intranigral injection of alpha-synuclein pre-formed fibrils leads to BBB compromise and bilateral dopaminergic neurodegeneration in A53T alpha-synuclein transgenic mice
Article Title: Intranigral injection of alpha-synuclein pre-formed fibrils leads to BBB compromise and bilateral dopaminergic neurodegeneration in A53T alpha-synuclein transgenic mice
Article References: Ghosh, S., Lin, H. H., Chu, S., Ngu, H., Zang, N., Raman, R., Stark, K., Foreman, O., Hashemifar, S., Easton, A., Bingol, B., & Meilandt, W. J. (2026). Intranigral injection of alpha-synuclein pre-formed fibrils leads to BBB compromise and bilateral dopaminergic neurodegeneration in A53T alpha-synuclein transgenic mice. Discover Neuroscience, 21(1), Article 89. https://doi.org/10.1186/s13064-026-00286-1
Image Credits: AI Generated
DOI: 10.1186/s13064-026-00286-1
Keywords: Intranigral, injection, alpha-synuclein, pre-formed, fibrils, leads, compromise, bilateral, dopaminergic, neurodegeneration, A53T, transgenic
News Source: Cassandra Pierce. (November 9, 2026). Synuclein Fibrils Trigger Rapid Bilateral Brain Damage in Mice. Scienmag.
